Needham on Neogenomics (NEO): 'We view today's sell-off as an overreaction and recommend buying shares on today's weakness'
Tweet Send to a Friend
Needham analyst Mike Matson reiterated a Buy rating and $19.00 price target on Neogenomics (NASDAQ: NEO)The analyst comments "This morning ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
